Clinical trial coordinators from the Walter Reed Army Institute of Research display samples in preparation for the RV575 research study at the Walter Reed Army Institute of Research Sept. 27. In October, the U.S. Military HIV Research Program will launch the Phase 1 study, evaluating varying doses of the Army's novel ALFQ adjuvant in a candidate HIV vaccine to determine the optimal adjuvant dosage level. (U.S. Army photo by Mike Walters/ Released)